Orna Therapeutics, Inc. is a biotechnology company developing medicines based on engineered circular RNA. The company designs and manufactures circular RNA constructs and lipid nanoparticle delivery systems to drive durable in vivo expression of therapeutic proteins.
Orna’s platform is applied to genetic medicines and cell engineering, including programs that aim to generate CAR-T cells inside the patient and other applications across immunology and oncology. Its work spans discovery through early clinical development, with an emphasis on scalable RNA and nanoparticle formulation capabilities to enable systemic delivery and targeted activity.
